UY34909A - Composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea. - Google Patents

Composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea.

Info

Publication number
UY34909A
UY34909A UY34909A UY34909A UY34909A UY 34909 A UY34909 A UY 34909A UY 34909 A UY34909 A UY 34909A UY 34909 A UY34909 A UY 34909A UY 34909 A UY34909 A UY 34909A
Authority
UY
Uruguay
Prior art keywords
iletil
fluorophenil
piridazin
benzotiazol
morfolin
Prior art date
Application number
UY34909A
Other languages
English (en)
Inventor
Authelin Jean-Rene
Sylvie Assadourian
Tsiala Benard
Goulaouic Helene
Amandine Mathieu
Perachia Maria-Teresa
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY34909A publication Critical patent/UY34909A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención se refiere a una composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea y a su uso en el tratamiento del cáncer.
UY34909A 2012-07-12 2013-07-12 Composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea. UY34909A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305840 2012-07-12

Publications (1)

Publication Number Publication Date
UY34909A true UY34909A (es) 2013-11-29

Family

ID=48782350

Family Applications (1)

Application Number Title Priority Date Filing Date
UY34909A UY34909A (es) 2012-07-12 2013-07-12 Composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea.

Country Status (25)

Country Link
US (1) US20150119391A1 (es)
EP (1) EP2872119A1 (es)
JP (1) JP2015525754A (es)
KR (1) KR20150030761A (es)
CN (1) CN104470500A (es)
AR (1) AR091727A1 (es)
AU (1) AU2013288676A1 (es)
BR (1) BR112015000497A2 (es)
CA (1) CA2878500A1 (es)
CL (1) CL2015000074A1 (es)
CO (1) CO7160069A2 (es)
CR (1) CR20150005A (es)
EA (1) EA201590199A1 (es)
HK (1) HK1209642A1 (es)
IL (1) IL236662A0 (es)
IN (1) IN2015KN00075A (es)
MA (1) MA37753B1 (es)
MX (1) MX2015000532A (es)
PH (1) PH12015500060A1 (es)
SG (1) SG11201500123XA (es)
TN (1) TN2015000011A1 (es)
TW (1) TW201402121A (es)
UY (1) UY34909A (es)
WO (1) WO2014009500A1 (es)
ZA (1) ZA201500129B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
CN1774259B (zh) * 2003-01-14 2011-12-28 特瓦制药工业有限公司 治疗系统性红斑狼疮的肽的胃肠道外制剂
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
US20100331357A1 (en) * 2008-02-28 2010-12-30 Takeda Pharmaceutical Company Limited Pharmaceutical composition
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Also Published As

Publication number Publication date
MX2015000532A (es) 2015-05-15
SG11201500123XA (en) 2015-02-27
AU2013288676A1 (en) 2015-02-05
ZA201500129B (en) 2015-12-23
MA37753A3 (fr) 2018-05-31
CO7160069A2 (es) 2015-01-15
CL2015000074A1 (es) 2015-06-12
EA201590199A1 (ru) 2015-05-29
MA37753A2 (fr) 2016-06-30
EP2872119A1 (en) 2015-05-20
HK1209642A1 (en) 2016-04-08
IN2015KN00075A (es) 2015-07-31
JP2015525754A (ja) 2015-09-07
MA37753B1 (fr) 2019-04-30
IL236662A0 (en) 2015-02-26
BR112015000497A2 (pt) 2017-06-27
WO2014009500A1 (en) 2014-01-16
TW201402121A (zh) 2014-01-16
US20150119391A1 (en) 2015-04-30
CN104470500A (zh) 2015-03-25
CR20150005A (es) 2015-04-06
AR091727A1 (es) 2015-02-25
PH12015500060A1 (en) 2015-03-02
CA2878500A1 (en) 2014-01-16
KR20150030761A (ko) 2015-03-20
TN2015000011A1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
UY39887A (es) (r)-(2-cloro-3-(trifluorometil)fenil)(1-(5-fluoropirimidin2-il)-4-metil-6,7-dihidro-1h-[1,2,3]triazolo-[4,5-c]piridin5(4h)-il)metanona como modulador del receptor p2x7
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
JO3433B1 (ar) حلقة كاربوكسامايد ذات أربع أعضاء للاستخدام كمبيدات النيماتودا
CU20140090A7 (es) COMPUESTOS ß- LACTÁMICOS SUSTITUIDOS CON AMINA, SU PREPARACIÓN Y USO COMO AGENTES BACTERIANOS
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
PH12014502169A1 (en) N-cyclylamides as nematicides
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
RS53818B1 (en) PIROLOBENZODIAZEPINI I NJIHOVI conjugated
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY33801A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
CR20130539A (es) Triazolopiridinas
PH12017500839A1 (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
MX346248B (es) Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2.
PH12015502665A1 (en) Improvements in or relating to organic compounds
PH12015502409A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
AR093527A1 (es) 6-((S)-1-1-[5-(2-HIDROXI-ETOXI)-PIRIDIN-2-IL]1H-PIRAZOL-3-IL-ETIL)-3H-1,3-BENZOTIAZOL-2-ONA COMO UN ANTAGONISTA DEL RECEPTOR AMPA DEPENDIENTE DE TARP-g 8
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.
MY197244A (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
UY34072A (es) Derivados sustituidos de indol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210602